BackGenmab A/S Overview

Genmab A/S Current Cash

Latest current cash for GNMSF: $1.5B.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$1.50B
↑ 15.97% YoYΔ $207.00M vs prior year quarter

Peer trimmed avg / median

Loading

Genmab A/S Current Cash History

Loading

Genmab A/S vs. peers: Current Cash Comparison

Loading

Genmab A/S Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Genmab A/S (GNMSF) FAQ

As of the most recent data (June 2026), GNMSF shows a current cash of $1.5B. That compares with $1.3B in the prior-year period — up 16.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GNMSF's current cash is now $1.5B (was $1.3B) — a 16.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Genmab A/S is outperforming or lagging.

Tracking GNMSF's current cash over time shows whether Genmab A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $1.5B That compares with $1.3B in the prior-year period — up 16.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Genmab A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $1.5B) with ownership activity and broader fundamentals.

Genmab A/S's current cash is $1.5B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.